OBJECTIVE: To study the effectiveness of the Haemophilus influenzae type b (Hib) vaccination program in Uganda. METHODS: Case-control study of Hib vaccine effectiveness against Hib meningitis. Cases were children hospitalized with Hib meningitis confirmed by culture and/or latex agglutination. Cases were identified retrospectively from July 2002 to July 2004, and prospectively from July 2004 to July 2005. Each case-patient was matched by age to three neighbourhood and three hospital controls; all children were eligible to receive Hib vaccine through the routine schedule. Vaccine effectiveness was evaluated by conditional logistic regression, controlling for confounding variables. RESULTS: We enrolled 41 cases; their median age was 6 months. Only six (15%) cases, all HIV-negative, had received >/=2 doses of Hib vaccine, compared with 64% of neighbourhood controls and 70% of hospital controls. Controlling for maternal education, the only variable which remained in the multivariable model, vaccine effectiveness for two or three doses vs. no dose was 99% [95% confidence intervals (CI) 92-100%] and 96% (95% CI 80-100%) when cases were compared with neighbourhood and hospital controls, respectively. CONCLUSION: In Uganda, Hib vaccine was highly effective in the context of the routine immunization schedule. Sustained routine use of Hib vaccine will contribute to the prevention of childhood morbidity and mortality.
OBJECTIVE: To study the effectiveness of the Haemophilus influenzae type b (Hib) vaccination program in Uganda. METHODS: Case-control study of Hib vaccine effectiveness against Hib meningitis. Cases were children hospitalized with Hib meningitis confirmed by culture and/or latex agglutination. Cases were identified retrospectively from July 2002 to July 2004, and prospectively from July 2004 to July 2005. Each case-patient was matched by age to three neighbourhood and three hospital controls; all children were eligible to receive Hib vaccine through the routine schedule. Vaccine effectiveness was evaluated by conditional logistic regression, controlling for confounding variables. RESULTS: We enrolled 41 cases; their median age was 6 months. Only six (15%) cases, all HIV-negative, had received >/=2 doses of Hib vaccine, compared with 64% of neighbourhood controls and 70% of hospital controls. Controlling for maternal education, the only variable which remained in the multivariable model, vaccine effectiveness for two or three doses vs. no dose was 99% [95% confidence intervals (CI) 92-100%] and 96% (95% CI 80-100%) when cases were compared with neighbourhood and hospital controls, respectively. CONCLUSION: In Uganda, Hib vaccine was highly effective in the context of the routine immunization schedule. Sustained routine use of Hib vaccine will contribute to the prevention of childhood morbidity and mortality.
Authors: James T Gaensbauer; Jeremy T Rakhola; Carolyne Onyango-Makumbi; Michael Mubiru; Jamie E Westcott; Nancy F Krebs; Edwin J Asturias; Mary Glenn Fowler; Elizabeth McFarland; Edward N Janoff Journal: Clin Vaccine Immunol Date: 2014-10-08
Authors: Awoere T Chinawa; Josephat M Chinawa; Edmund N Ossai; Nduagubam Obinna; Vivian Onukwuli; Ann E Aronu; Chuka P Manyike Journal: Hum Vaccin Immunother Date: 2021-10-06 Impact factor: 4.526
Authors: Rosamund F Lewis; Annet Kisakye; Bradford D Gessner; Chaplain Duku; John Bosco Odipio; Robert Iriso; Denis Nansera; Fiona Braka; Issa Makumbi; Addy Kekitiinwa Journal: Bull World Health Organ Date: 2008-04 Impact factor: 9.408
Authors: D Allen Roberts; Marie Ng; Gloria Ikilezi; Anne Gasasira; Laura Dwyer-Lindgren; Nancy Fullman; Talemwa Nalugwa; Moses Kamya; Emmanuela Gakidou Journal: BMC Med Date: 2015-12-03 Impact factor: 8.775